{"id":"W2997720498","doi":"10.1001/jamaoncol.2019.5570","title":"Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo","year":2020,"lang":"en","type":"article","venue":"JAMA Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":436,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Pharmacyclics; Genentech; Merck Canada; Deutschen Konsortium für Translationale Krebsforschung; Radboud Universitair Medisch Centrum; Melanoma Institute Australia; Amgen; Radboud Universiteit; Universitat de Barcelona; Astellas Pharma; Les Laboratories Pierre Fabre; European Organisation for Research and Treatment of Cancer; SkylineDx; Sun Pharma; Peter MacCallum Cancer Centre; Syndax Pharmaceuticals; Regeneron Pharmaceuticals; Endocyte; Array BioPharma; Aix-Marseille Université; InflaRx; Pfizer; Incyte; F. Hoffmann-La Roche; Sanofi; GlaxoSmithKline; NeraCare; University of Sydney; Medizinischen Hochschule Hannover; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Pembrolizumab; Internal medicine; Adverse effect; Placebo; Randomized controlled trial; Clinical trial; Melanoma; Oncology; Surgery; Cancer; Immunotherapy; Pathology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002572226,0.0005970428,0.00190792,0.000286079,0.0002634638,0.000537416,0.0004025092,0.001156659,0.003077613],"category_scores_gemma":[0.00441125,0.0004080476,0.001834099,0.000264951,0.000500576,0.0006055988,0.0002987712,0.001325701,0.000324382],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003434517,"about_ca_system_score_gemma":0.0004864749,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003294666,"about_ca_topic_score_gemma":0.0005292928,"domain_scores_codex":[0.9984315,0.0008792738,0.0001612167,0.000287188,0.0001091649,0.0001316437],"domain_scores_gemma":[0.9975244,0.0009097889,0.0008778285,0.0001553438,0.0001077484,0.0004248599],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9661418,0.002467894,0.01541815,0.0003426535,0.001560958,0.00003181084,0.00003899546,0.0001998112,0.001449115,0.00005146576,0.000390963,0.01190635],"study_design_scores_gemma":[0.6279935,0.2557023,0.1066103,0.0001338751,0.003852879,0.0001540288,0.00006722316,0.001943465,0.001343671,0.0005480651,0.001596832,0.00005382188],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9950331,0.002493624,0.0002812408,0.0002361226,0.0001754843,0.000615289,0.0004273541,0.00001463834,0.0007230777],"genre_scores_gemma":[0.997221,0.0004359474,0.0002728639,0.0002705569,0.0001744681,0.0007539578,0.0002920559,0.000003282277,0.0005758494],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003077613,"threshold_uncertainty_score":0.01360339,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01442860837970582,"score_gpt":0.2701461534137153,"score_spread":0.2557175450340095,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}